Enzo acquires Uveitis drug candidate.(Brief Article)

Acquiring the rights and intellectual property from two German university scientists, Enzo Biochem Inc. has expanded its immune regulation portfolio to include a candidate to treat uveitis, an eye disease that can lead to blindness. Based in Farmingdale, N.Y., Enzo is developing a gene medicine for HIV-1 infection and immune regulation medicines for hepatitis B, hepatitis C and Crohn's disease. The newly acquired candidate for uveitis also is designed as an immune …